Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2022

01-02-2022 | Acute Kidney Injury

Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid

Authors: Toshiki Kuno, Matsuo So, Mai Takahashi, Natalia N. Egorova

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2022

Login to get access

Abstract

Previous observational and randomized studies suggested potential benefit of therapeutic anticoagulation during hospitalization, but this treatment remains controversial. As of June 30th 2021, steroids is the standard treatment of COVID patients. We aimed to investigate the association of prophylactic and therapeutic anticoagulation with mortality for patients with COVID-19 who were treated with steroids. We retrospectively reviewed the medical records of 2533 patients discharged between March 1st, 2020 and March 30th, 2021, with laboratory-confirmed COVID-19 in the Mount Sinai Health System and treated with steroids. We evaluated the effect of therapeutic versus prophylactic anticoagulation on the outcomes using propensity score analyses. Subgroup analyses were conducted by stratification of patients by endotracheal intubation. Among the 2533 eligible patients, 465 (18.4%) received therapeutic anticoagulation. After 1:1 propensity score matching (N = 383 pairs), in-hospital mortality was similar between those with therapeutic versus prophylactic anticoagulation (36.0% versus 30.0%, P = 0.091). In-hospital mortality regardless of endotracheal intubation were not significantly different between the two groups. Therapeutic anticoagulation was not associated with reduced or increased risk of in-hospital mortality in patients with COVID-19 treated with steroids.
Appendix
Available only for authorised users
Literature
1.
Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E et al (2020) Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 76(16):1815–1826CrossRef
2.
3.
Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324(13):1330–41CrossRef
4.
5.
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 369:m1966CrossRef
6.
Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA et al (2020) Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122–124CrossRef
7.
8.
9.
10.
Takahashi M, Egorova NN, Kuno T (2021) COVID-19 and influenza testing in New York City. J Med Virol 93(2):698–701CrossRef
11.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330CrossRef
12.
Chandiramani R, Cao D, Nicolas J, Mehran R (2020) Contrast-induced acute kidney injury. Cardiovasc Interv Ther 35(3):209–217CrossRef
13.
Austin PC (2009) The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak 29(6):661–677CrossRef
14.
Yokoyama Y, Briasoulis A, Takagi H, Kuno T (2020) Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res 288:198137CrossRef
15.
16.
Acosta-Ochoa I, Bustamante-Munguira J, Mendiluce-Herrero A, Bustamante-Bustamante J, Coca-Rojo A (2019) Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function. J Clin Med 8(9):1323CrossRef
17.
Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8(7):681–686CrossRef
18.
Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G (2020) Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29(12):105288CrossRef
19.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med 382(17):e38CrossRef
20.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 75(23):2950–2973CrossRef
21.
Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J et al (2020) Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 142(2):114–128CrossRef
22.
Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A (2020) Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC Case Rep 2(9):1383–1387CrossRef
23.
Spyropoulos AC, Weitz JI (2020) Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm. Circulation 142(2):129–132CrossRef
24.
Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB et al (2020) Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol 76(18):2060–2072CrossRef
25.
Konstantinides SV (2020) Thrombosis and thromboembolism related to COVID-19: increase the level of awareness, lower the threshold of suspicion, and keep following the guidelines. JACC Case Rep 2(9):1388–1390CrossRef
26.
Tritschler T, Mathieu ME, Skeith L, Rodger M, Middeldorp S, Brighton T et al (2020) Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 18:2958CrossRef
27.
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M et al (2020) Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 17(5):491–500CrossRef
28.
Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D’Amico R et al (2020) Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials 21(1):574CrossRef
29.
30.
31.
Investigators R-C, Investigators AC-a, Investigators A, Goligher EC, Bradbury CA, McVerry BJ et al (2021) Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med 385(9):777–89CrossRef
32.
Investigators A, Investigators AC-a, Investigators R-C, Lawler PR, Goligher EC, Berger JS et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med 385(9):790–802CrossRef
Metadata
Title
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid
Authors
Toshiki Kuno
Matsuo So
Mai Takahashi
Natalia N. Egorova
Publication date
01-02-2022
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2022
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02569-2

Other articles of this Issue 2/2022

Journal of Thrombosis and Thrombolysis 2/2022 Go to the issue

BriefCommunication

Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid

OriginalPaper

Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes

OriginalPaper

Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI

OriginalPaper

Clinical outcomes of surgical embolectomy versus catheter-directed thrombolysis for acute limb ischemia: a nationwide cohort study

OriginalPaper

Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics

Editorial

Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits